海南海藥(000566.SZ)第三季度預虧3000萬–4000萬元 同比盈轉虧
格隆匯 10 月 14日丨海南海藥(000566.SZ)公佈,預計2020年前三季度歸屬於上市公司股東的淨利潤1500萬元–2200萬元,同比下降82.13%-87.82%;其中,第三季度歸屬於上市公司股東的淨虧損3000萬元–4000萬元,上年同期盈利4203.25萬元。業績變動的主要原因如下:
1、年初受新冠肺炎疫情的影響,導致公司及客户復工復產延遲;公司生產所需原料藥、中間體大幅漲價,導致生產成本上漲;全國醫院提供診療服務、病人就診均受到不同程度的影響,藥品終端需求嚴重下降,導致公司產品營業收入同比下降。隨着國內疫情得到有效控制,公司生產經營逐步恢復到正常狀態並呈現良好的發展態勢。
2、中國抗體制藥有限公司於2019年11月12日在香港聯合交易所主板上市。公司持有其15.11%股權,2020年前三季度根據市場價格計量該持有股權公允價值變動損益,預計上述非經常性損益對公司利潤影響金額約-1454.75萬元。
3、公司致力於產品的深度研發,提高產品的質量水平及科技含量,積極推進仿製藥質量和療效一致性評價工作。本報告期加大對派恩加濱原料及製劑I期臨牀研究、氟非尼酮膠囊的I期臨牀研究、抗病毒藥物應急研發、人工耳蝸技術開發等項目的投資以致研發費用化金額增加,預計對利潤影響金額約-4533.28萬元。
綜合上述因素,公司2020年前三季度的生產經營受到一定影響,以致本報告期歸屬於上市公司股東的淨利潤較上年同期有所下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.